Latest On AnaptysBio, Inc (ANAB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-22 18:46 EST | News | AnaptysBio upgraded to neutral at JP Morgan on clinical execution | N/A |  |
| 2023-05-21 00:00 EST | News | Stocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare Conferences | N/A | |
| 2023-05-18 17:01 EST | News | AnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agents | N/A | |
| 2023-05-12 06:14 EST | News | AnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48M | N/A | |
| 2023-04-25 14:45 EST | News | GSK's Jemperli gets review in EU for expanded use in uterus cancer | N/A | |
| 2023-03-31 01:05 EST | News | AnaptysBio: Upside Could Be Lying Ahead Very Nicely | N/A | |
| 2023-03-01 22:46 EST | News | AnaptysBio GAAP EPS of -$0.93, revenue of $6.8M | N/A | |
| 2023-01-13 19:42 EST | News | AnaptysBio rises 10% on stock repurchase of up to $50M | N/A | |
| 2022-11-09 02:12 EST | News | AnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14M | N/A | |
| 2022-11-01 22:23 EST | News | AnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonists | N/A | |
| 2022-10-05 18:17 EST | News | AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial | N/A | |
| 2022-09-14 00:51 EST | News | AnaptysBio cut to Hold at Truist citing high bar for hair loss treatment | N/A | |
| 2022-09-12 13:42 EST | News | AnaptysBio sells royalties from GSK-partnered Zejula for $45M | N/A | |
| 2022-09-01 01:51 EST | News | AnaptysBio skin condition candidate fails mid-stage trial; shares down 16% | N/A | |
| 2022-08-08 18:55 EST | News | AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M | N/A | |
| 2022-05-04 22:42 EST | News | AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M | N/A | |
| 2022-03-22 16:43 EST | News | AnaptysBio names interim CEO as Hamza Suria steps down | N/A | |
| 2022-03-22 16:42 EST | News | AnaptysBio cut to neutral at Guggenheim on future of pipeline | N/A | |
| 2022-03-14 23:38 EST | News | AnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12% | N/A | |
| 2021-11-05 01:02 EST | News | AnaptysBio EPS beats by $0.64, beats on revenue | N/A | |
| 2021-10-26 12:05 EST | News | AnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with Sagard | N/A | |
| 2021-10-04 23:16 EST | News | AnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasis | N/A | |
| 2021-08-18 04:46 EST | News | AnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approval | N/A | |
| 2021-08-18 04:46 EST | News | ANAB, TLRY, PFMT and BMRN among after hours movers | N/A | |
| 2021-08-09 22:59 EST | News | AnaptysBio EPS beats by $0.12, beats on revenue | N/A | |
| 2021-07-20 18:44 EST | News | AnaptysBio gains after report the company received a takeover offer | N/A | |
| 2021-05-05 11:31 EST | News | AnaptysBio EPS beats by $0.03, beats on revenue | N/A | |
| 2021-04-24 05:15 EST | News | AnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone payment | N/A | |
| 2021-04-24 05:14 EST | News | GlaxoSmithKline wins EU approval for Jemperli in endometrial cancer | N/A | |
| 2021-04-23 07:49 EST | News | AnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated) | N/A | |
| 2021-03-17 12:05 EST | Analyst Rating | The Analyst Target Price has increased from $26.75 to $28.5. | Buy | |
| 2021-03-16 19:18 EST | News | AnaptysBio is set for a catalyst-rich phase after the recent selloff: Truist | N/A | |
| 2021-03-10 15:05 EST | Analyst Rating | The Analyst Target Price has decreased from $30.75 to $26.75. | Neutral | |
| 2021-03-09 03:06 EST | Analyst Rating | The Analyst Target Price has decreased from $33.25 to $30.75. | Neutral | |
| 2021-03-08 17:28 EST | News | AnaptysBio fails in mid-stage study for Imsidolimab in skin disease | N/A | |
| 2021-03-08 17:27 EST | News | AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure | N/A | |
| 2021-03-03 02:39 EST | News | AnaptysBio: Upcoming Catalyst Seems Like Quite The Gamble | N/A | |
| 2021-03-01 15:05 EST | Analyst Rating | The Analyst Target Price has increased from $29.8 to $33.25. | Buy | |
| 2021-03-01 15:05 EST | Earnings Estimate | An EPS average of -$2.43 is estimated for the 2022 year. | Sell | |
| 2021-03-01 15:05 EST | Earnings Estimate | An EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-26 15:05 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-25 19:20 EST | News | AnaptysBio EPS beats by $0.15, beats on revenue | N/A | |
| 2021-02-12 11:05 EST | Analyst Rating | The Analyst Target Price has increased from $28 to $29.8. | Neutral | |
| 2021-02-11 20:59 EST | News | AnaptysBio rises after double-upgrade from JPM; positive risk/reward profile cited | N/A | |
| 2021-02-11 20:58 EST | News | AnaptysBio: Troubled History Of Drug Development | N/A | |
| 2020-12-13 03:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-01 10:36 EST | News | AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside | N/A | |
| 2020-11-18 06:57 EST | News | AnaptysBio (ANAB) Investor Presentation - Slideshow | N/A | |
| 2020-11-15 11:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 11:07 EST | Analyst Rating | The Analyst Target Price has increased from $27.5 to $28. | Neutral | |
About AnaptysBio, Inc (ANAB):
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
General
- Name AnaptysBio, Inc
- Symbol ANAB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 94
- Fiscal Year EndDecember
- IPO Date2017-01-26
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.anaptysbio.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 8.07
- Price/Book (Most Recent Quarter) 1.53
- Enterprise Value Revenue 2.85
- Enterprise Value EBITDA 0.11
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$3.01
- Next Year EPS Estimate -$3.09
- Next Quarter EPS Estimate -$0.61
- Profit Margin -27%
- Operating Margin -32%
- Return on Assets -4%
- Return on Equity -5%
- Revenue 75 million
- Earnings Per Share -$3.01
- Revenue Per Share $2.75
- Gross Profit -5025000
- Quarterly Earnings Growth 1900%
View More
Highlights
- Market Capitalization 587.28 million
- EBITDA -87543000
- PE Ratio -6.14
- Analyst Target Price $28.5
- Book Value Per Share $14.50
View More
Share Statistics
- Shares Outstanding 27.37 million
- Shares Float 15.89 million
- % Held by Insiders 77%
- % Held by Institutions 106.22%
- Shares Short 3.81 million
- Shares Short Prior Month 3.74 million
- Short Ratio 8.99
- Short % of Float 21%
- Short % of Shares Outstanding 14%
View More
Technicals
- Beta 0.13
- 52 Week High $35.86
- 52 Week Low $12.46
- 50 Day Moving Average 26.72
- 200 Day Moving Average 23.55
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
AnaptysBio, Inc (ANAB) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
AnaptysBio, Inc (ANAB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $60 million | $1.20 | $0.60 | 98.87% |
| 2020-09-30 | 2020-11-04 | $N/A | -$0.87 | -$0.69 | -26.45% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.79 | -$0.65 | -21.18% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.30 | -$0.80 | 62.5% |
| 2019-12-31 | 2020-03-02 | $3 million | -$0.75 | -$1.28 | 41.36% |
| 2019-09-30 | 2019-11-08 | $N/A | -$1.15 | -$1.14 | -0.46% |
| 2019-06-30 | 2019-08-08 | $5 million | -$0.89 | -$0.95 | 6.66% |
| 2019-03-31 | 2019-05-07 | $N/A | -$0.82 | -$0.78 | -4.75% |
| 2018-12-31 | 2019-02-28 | $N/A | -$0.64 | -$0.86 | 25.93% |
| 2018-09-30 | 2018-11-08 | $5 million | -$0.66 | -$0.70 | 6.16% |
| 2018-06-30 | 2018-08-07 | $N/A | -$0.57 | -$0.67 | 14.41% |
| 2018-03-31 | 2018-05-08 | $N/A | -$0.63 | -$0.46 | -36.22% |
| 2017-12-31 | 2018-03-05 | $3 million | -$0.30 | -$0.42 | 28.37% |
| 2017-09-30 | 2017-11-07 | $-7000000 | -$0.45 | -$0.47 | 4.56% |
| 2017-06-30 | 2017-08-10 | $7 million | -$0.13 | -$0.42 | 69.34% |
| 2017-03-31 | 2017-05-11 | $N/A | -$0.75 | -$0.18 | -310.96% |
| 2016-12-31 | 2017-03-08 | $2.75 million | -$0.19 | -$0.10 | -86.34% |
AnaptysBio, Inc (ANAB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
AnaptysBio, Inc (ANAB) Chart:
AnaptysBio, Inc (ANAB) News:
Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
AnaptysBio, Inc (ANAB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-19 | 12.5 | 10.5 | CALL | 0 | 0 | 544.05 | TRUE | 0 | 0 |
| 2025-12-19 | 15 | 0 | CALL | 0 | 0 | 471.59 | TRUE | 0 | 0 |
| 2025-12-19 | 17.5 | 7.7 | CALL | 0 | 7 | 421.88 | TRUE | 0 | 0 |
| 2025-12-19 | 20 | 23.9 | CALL | 0 | 545 | 185.44 | TRUE | 0 | 0 |
| 2025-12-19 | 22.5 | 21.4 | CALL | 0 | 568 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 25 | 0 | CALL | 0 | 0 | 273.46 | TRUE | 0 | 0 |
| 2025-12-19 | 30 | 15.2 | CALL | 0 | 191 | 202.68 | TRUE | 0 | 0 |
| 2025-12-19 | 35 | 9.38 | CALL | 0 | 72 | 146.08 | TRUE | 0 | 0 |
| 2025-12-19 | 40 | 4.75 | CALL | 0 | 20 | 104.22 | TRUE | 0 | 0 |
| 2025-12-19 | 45 | 1.98 | CALL | 0 | 33 | 80.89 | TRUE | 0 | 0 |
| 2025-12-19 | 50 | 0.5 | CALL | 0 | 1 | 241.43 | FALSE | 0 | 0 |
| 2025-12-19 | 55 | 1.25 | CALL | 0 | 1 | 296.68 | FALSE | 0 | 0 |
| 2025-12-19 | 12.5 | 0.01 | PUT | 0 | 1634 | 1239.5 | FALSE | 0 | 0 |
| 2025-12-19 | 15 | 1.2 | PUT | 0 | 232 | 1065.67 | FALSE | 0 | 0 |
| 2025-12-19 | 17.5 | 0.07 | PUT | 0 | 1614 | 931.41 | FALSE | 0 | 0 |
| 2025-12-19 | 20 | 0.05 | PUT | 0 | 2401 | 601.11 | FALSE | 0 | 0 |
| 2025-12-19 | 22.5 | 0.2 | PUT | 0 | 81 | 729.53 | FALSE | 0 | 0 |
| 2025-12-19 | 25 | 0.1 | PUT | 0 | 188 | 649.17 | FALSE | 0 | 0 |
| 2025-12-19 | 30 | 0.15 | PUT | 0 | 2987 | 203.35 | FALSE | 0 | 0 |
| 2025-12-19 | 35 | 0.25 | PUT | 0 | 86 | 142.26 | FALSE | 0 | 0 |
| 2025-12-19 | 40 | 0.4 | PUT | 0 | 7 | 296.93 | FALSE | 0 | 0 |
| 2025-12-19 | 45 | 1.17 | PUT | 0 | 10 | 198.39 | FALSE | 0 | 0 |
| 2025-12-19 | 50 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 55 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 12.5 | 10 | CALL | 0 | 2 | 252.06 | TRUE | 0 | 0 |
| 2026-01-16 | 15 | 8.6 | CALL | 0 | 6 | 217.61 | TRUE | 0 | 0 |
| 2026-01-16 | 17.5 | 7.67 | CALL | 0 | 51 | 188.96 | TRUE | 0 | 0 |
| 2026-01-16 | 20 | 20.8 | CALL | 0 | 17 | 159.21 | TRUE | 0 | 0 |
| 2026-01-16 | 22.5 | 14.29 | CALL | 0 | 0 | 142.93 | TRUE | 0 | 0 |
| 2026-01-16 | 25 | 12.96 | CALL | 0 | 16 | 123.77 | TRUE | 0 | 0 |
| 2026-01-16 | 30 | 13.85 | CALL | 0 | 1 | 104.94 | TRUE | 0 | 0 |
| 2026-01-16 | 35 | 6.8 | CALL | 0 | 9 | 84.59 | TRUE | 0 | 0 |
| 2026-01-16 | 40 | 2.69 | CALL | 0 | 79 | 76.09 | TRUE | 0 | 0 |
| 2026-01-16 | 45 | 4.5 | CALL | 6 | 19 | 70.75 | TRUE | 4.5 | 0 |
| 2026-01-16 | 50 | 5.2 | CALL | 0 | 1 | 112.95 | FALSE | 0 | 0 |
| 2026-01-16 | 55 | 0.85 | CALL | 0 | 2 | 122.99 | FALSE | 0 | 0 |
| 2026-01-16 | 60 | 0 | CALL | 0 | 0 | 158.67 | FALSE | 0 | 0 |
| 2026-01-16 | 12.5 | 0.15 | PUT | 0 | 45 | 331.77 | FALSE | 0 | 0 |
| 2026-01-16 | 15 | 0.65 | PUT | 0 | 2 | 387.32 | FALSE | 0 | 0 |
| 2026-01-16 | 17.5 | 1.91 | PUT | 0 | 6 | 440.1 | FALSE | 0 | 0 |
| 2026-01-16 | 20 | 0.32 | PUT | 0 | 182 | 200.45 | FALSE | 0 | 0 |
| 2026-01-16 | 22.5 | 0.44 | PUT | 0 | 2 | 315.95 | FALSE | 0 | 0 |
| 2026-01-16 | 25 | 2.9 | PUT | 0 | 11 | 306.95 | FALSE | 0 | 0 |
| 2026-01-16 | 30 | 0.2 | PUT | 1676 | 4029 | 82.57 | FALSE | 0.2 | 0 |
| 2026-01-16 | 35 | 0.46 | PUT | 0 | 2018 | 118.59 | FALSE | 0 | 0 |
| 2026-01-16 | 40 | 1.46 | PUT | 1 | 2 | 68.98 | FALSE | 1.46 | 0 |
| 2026-01-16 | 45 | 0 | PUT | 0 | 0 | 55.42 | FALSE | 0 | 0 |
| 2026-01-16 | 50 | 0 | PUT | 0 | 0 | 54.71 | TRUE | 0 | 0 |
| 2026-01-16 | 55 | 0 | PUT | 0 | 0 | 55.5 | TRUE | 0 | 0 |
| 2026-01-16 | 60 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2026-02-20 | 12.5 | 20.7 | CALL | 0 | 53 | 175.26 | TRUE | 0 | 0 |
| 2026-02-20 | 15 | 0 | CALL | 0 | 0 | 150.38 | TRUE | 0 | 0 |
| 2026-02-20 | 17.5 | 20.3 | CALL | 0 | 0 | 129.7 | TRUE | 0 | 0 |
| 2026-02-20 | 20 | 21.9 | CALL | 0 | 2 | 112 | TRUE | 0 | 0 |
| 2026-02-20 | 22.5 | 17.7 | CALL | 0 | 0 | 100.11 | TRUE | 0 | 0 |
| 2026-02-20 | 25 | 20.3 | CALL | 0 | 4 | 99.33 | TRUE | 0 | 0 |
| 2026-02-20 | 30 | 13.7 | CALL | 0 | 16 | 80.07 | TRUE | 0 | 0 |
| 2026-02-20 | 35 | 9.7 | CALL | 0 | 14 | 75.62 | TRUE | 0 | 0 |
| 2026-02-20 | 40 | 5.6 | CALL | 0 | 33 | 66.62 | TRUE | 0 | 0 |
| 2026-02-20 | 45 | 4.75 | CALL | 0 | 4001 | 74.83 | TRUE | 0 | 0 |
| 2026-02-20 | 50 | 3.61 | CALL | 0 | 15 | 63.12 | FALSE | 0 | 0 |
| 2026-02-20 | 55 | 0.05 | CALL | 0 | 6 | 67.42 | FALSE | 0 | 0 |
| 2026-02-20 | 60 | 0 | CALL | 0 | 0 | 113.66 | FALSE | 0 | 0 |
| 2026-02-20 | 65 | 0 | CALL | 0 | 0 | 126.67 | FALSE | 0 | 0 |
| 2026-02-20 | 12.5 | 1.95 | PUT | 0 | 2 | 418.01 | FALSE | 0 | 0 |
| 2026-02-20 | 15 | 3.28 | PUT | 0 | 6 | 309.8 | FALSE | 0 | 0 |
| 2026-02-20 | 17.5 | 1.55 | PUT | 0 | 1 | 249.46 | FALSE | 0 | 0 |
| 2026-02-20 | 20 | 0 | PUT | 0 | 0 | 221.75 | FALSE | 0 | 0 |
| 2026-02-20 | 22.5 | 4.85 | PUT | 0 | 0 | 212.62 | FALSE | 0 | 0 |
| 2026-02-20 | 25 | 5.27 | PUT | 0 | 0 | 193.61 | FALSE | 0 | 0 |
| 2026-02-20 | 30 | 4.4 | PUT | 0 | 5 | 173.78 | FALSE | 0 | 0 |
| 2026-02-20 | 35 | 0 | PUT | 0 | 0 | 135.43 | FALSE | 0 | 0 |
| 2026-02-20 | 40 | 1.7 | PUT | 1 | 0 | 53.65 | FALSE | 1.7 | 0 |
| 2026-02-20 | 45 | 0 | PUT | 0 | 0 | 58.76 | FALSE | 0 | 0 |
| 2026-02-20 | 50 | 0 | PUT | 0 | 0 | 52.72 | TRUE | 0 | 0 |
| 2026-02-20 | 55 | 0 | PUT | 0 | 0 | 53.5 | TRUE | 0 | 0 |
| 2026-02-20 | 60 | 0 | PUT | 0 | 0 | 46.31 | TRUE | 0 | 0 |
| 2026-02-20 | 65 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2026-05-15 | 2.5 | 0 | CALL | 0 | 0 | 298.87 | TRUE | 0 | 0 |
| 2026-05-15 | 5 | 0 | CALL | 0 | 0 | 174.5 | TRUE | 0 | 0 |
| 2026-05-15 | 7.5 | 0 | CALL | 0 | 0 | 162.47 | TRUE | 0 | 0 |
| 2026-05-15 | 10 | 0 | CALL | 0 | 0 | 133.19 | TRUE | 0 | 0 |
| 2026-05-15 | 12.5 | 0 | CALL | 0 | 0 | 111.07 | TRUE | 0 | 0 |
| 2026-05-15 | 15 | 23.5 | CALL | 0 | 1 | 110.04 | TRUE | 0 | 0 |
| 2026-05-15 | 17.5 | 0 | CALL | 0 | 0 | 107.43 | TRUE | 0 | 0 |
| 2026-05-15 | 20 | 0 | CALL | 0 | 0 | 91.22 | TRUE | 0 | 0 |
| 2026-05-15 | 22.5 | 0 | CALL | 0 | 0 | 88 | TRUE | 0 | 0 |
| 2026-05-15 | 25 | 0 | CALL | 0 | 0 | 81.22 | TRUE | 0 | 0 |
| 2026-05-15 | 30 | 17.8 | CALL | 0 | 60 | 76.9 | TRUE | 0 | 0 |
| 2026-05-15 | 35 | 13.4 | CALL | 0 | 4 | 68.45 | TRUE | 0 | 0 |
| 2026-05-15 | 40 | 11.82 | CALL | 1 | 7 | 75.18 | TRUE | 11.82 | 0 |
| 2026-05-15 | 45 | 8.92 | CALL | 1 | 1 | 70.28 | TRUE | 8.92 | 0 |
| 2026-05-15 | 50 | 4 | CALL | 0 | 1 | 64.06 | FALSE | 0 | 0 |
| 2026-05-15 | 55 | 5 | CALL | 1 | 22 | 66.4 | FALSE | 5 | 0 |
| 2026-05-15 | 60 | 0 | CALL | 0 | 0 | 61.46 | FALSE | 0 | 0 |
| 2026-05-15 | 65 | 0 | CALL | 0 | 0 | 62.32 | FALSE | 0 | 0 |
| 2026-05-15 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-05-15 | 5 | 0 | PUT | 0 | 0 | 885.57 | FALSE | 0 | 0 |
| 2026-05-15 | 7.5 | 0 | PUT | 0 | 0 | 436.55 | FALSE | 0 | 0 |
| 2026-05-15 | 10 | 0 | PUT | 0 | 0 | 340.93 | FALSE | 0 | 0 |
| 2026-05-15 | 12.5 | 0 | PUT | 0 | 0 | 284.57 | FALSE | 0 | 0 |
| 2026-05-15 | 15 | 0 | PUT | 0 | 0 | 181.42 | FALSE | 0 | 0 |
| 2026-05-15 | 17.5 | 1.9 | PUT | 0 | 0 | 214.11 | FALSE | 0 | 0 |
| 2026-05-15 | 20 | 3.35 | PUT | 0 | 10 | 189.14 | FALSE | 0 | 0 |
| 2026-05-15 | 22.5 | 0 | PUT | 0 | 0 | 168.05 | FALSE | 0 | 0 |
| 2026-05-15 | 25 | 5.4 | PUT | 0 | 1 | 149.75 | FALSE | 0 | 0 |
| 2026-05-15 | 30 | 5.7 | PUT | 0 | 8 | 118.85 | FALSE | 0 | 0 |
| 2026-05-15 | 35 | 0 | PUT | 0 | 0 | 75.1 | FALSE | 0 | 0 |
| 2026-05-15 | 40 | 6.15 | PUT | 0 | 6 | 63.39 | FALSE | 0 | 0 |
| 2026-05-15 | 45 | 0 | PUT | 0 | 0 | 60.25 | FALSE | 0 | 0 |
| 2026-05-15 | 50 | 0 | PUT | 0 | 0 | 58.32 | TRUE | 0 | 0 |
| 2026-05-15 | 55 | 0 | PUT | 0 | 0 | 57.31 | TRUE | 0 | 0 |
| 2026-05-15 | 60 | 0 | PUT | 0 | 0 | 55.56 | TRUE | 0 | 0 |
| 2026-05-15 | 65 | 0 | PUT | 0 | 0 | 59.34 | TRUE | 0 | 0 |
Latest ANAB Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 8 | $21.35 |
| Jun 13, 2022 7:59 PM EST | 1 | $21.35 |
| Jun 13, 2022 7:59 PM EST | 200 | $21.35 |
| Jun 13, 2022 7:59 PM EST | 54 | $21.35 |
| Jun 13, 2022 7:59 PM EST | 13 | $21.35 |
AnaptysBio, Inc (ANAB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm |
| 2018-09-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm |
| 2018-10-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm |
| 2019-12-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm |
| 2020-02-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm |
| 2019-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm |
| 2019-11-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm |
| 2018-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm |
| 2018-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm |
| 2018-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm |
| 2018-05-15 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm |
| 2018-03-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm |
| 2018-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm |
| 2018-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm |
| 2018-09-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm |
| 2018-09-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm |
| 2018-09-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm |
| 2020-08-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm |
| 2018-03-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm |
| 2018-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm |
| 2018-04-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm |
| 2018-07-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm |
| 2018-08-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm |
| 2018-08-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm |
| 2018-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm |
| 2018-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-12-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm |
| 2019-04-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm |
| 2019-09-26 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm |
| 2019-09-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm |
| 2019-11-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm |
| 2019-12-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm |
| 2019-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm |
| 2019-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm |
| 2020-02-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm |
| 2020-02-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm |
| 2020-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm |
| 2020-07-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm |
| 2020-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm |
| 2020-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm |
| 2020-07-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm |
| 2020-07-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm |
| 2019-11-22 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm |
| 2018-06-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm |
| 2019-12-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm |
| 2019-08-19 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm |
| 2018-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm |
| 2018-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm |
| 2018-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm |
| 2018-05-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm |
| 2018-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm |
| 2018-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm |
| 2018-09-14 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm |
| 2018-09-14 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm |
| 2018-09-14 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm |
| 2018-09-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm |
| 2019-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm |
| 2019-02-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm |
| 2019-02-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm |
| 2019-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm |
| 2019-08-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm |
| 2019-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm |
| 2019-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm |
| 2020-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm |
| 2020-03-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm |
| 2020-03-02 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm |
| 2020-03-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm |
| 2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm |
| 2020-04-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm |
| 2020-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm |
| 2020-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm |
| 2020-10-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm |
| 2020-10-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm |
| 2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm |
| 2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm |
| 2020-04-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm |
AnaptysBio, Inc (ANAB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 77%Institutional Ownership: 10622%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 1,100.00 | 75.81 | 83,390.01 | 0.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 4,820.00 | 72.24 | 348,212.22 | 10,022.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 6,624.00 | 74.33 | 492,361.92 | 1,100.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-09-07 | Marco Londei | Chief Medical Officer | Buy | 142,857.00 | 0.70 | 99,999.90 | 144,877.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Sell | 6,741.00 | 68.47 | 461,577.84 | 144,877.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 18,604.00 | 71.33 | 1,327,060.53 | 14,842.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Sell | 8,002.00 | 67.57 | 540,683.94 | 151,618.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Buy | 8,048.00 | 0.70 | 5,633.60 | 152,925.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Sell | 3,185.00 | 66.38 | 211,416.16 | 159,620.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Sell | 12,120.00 | 65.36 | 792,177.74 | 162,805.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2018-12-17 | Marco Londei | Chief Medical Officer | Buy | 22,000.00 | 6.93 | 152,460.00 | 174,925.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm |
| 2019-06-10 | Hamza Suria | President, CEO | Sell | 454.00 | 76.31 | 34,644.74 | 17,636.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-06-10 | Hamza Suria | President, CEO | Sell | 1,994.00 | 75.86 | 151,270.82 | 18,090.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-06-10 | Hamza Suria | President, CEO | Sell | 5,000.00 | 74.68 | 373,412.50 | 20,084.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-01-15 | Marco Londei | Chief Medical Officer | Sell | 14,894.00 | 70.04 | 1,043,195.12 | 22,377.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm |
| 2019-06-04 | Marco Londei | Chief Medical Officer | Sell | 2,003.00 | 74.50 | 149,219.09 | 22,377.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm |
| 2019-06-04 | Marco Londei | Chief Medical Officer | Sell | 2,048.00 | 73.43 | 150,383.82 | 24,380.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm |
| 2019-06-10 | Hamza Suria | President, CEO | Sell | 6,440.00 | 73.70 | 474,637.02 | 25,084.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-06-04 | Marco Londei | Chief Medical Officer | Sell | 6,009.00 | 72.45 | 435,358.66 | 26,428.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 2,222.00 | 90.26 | 200,549.05 | 271,106.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 2,803.00 | 89.42 | 250,631.37 | 273,328.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-06-08 | Hamza Suria | President, CEO | Buy | 22,428.00 | 2.59 | 58,088.52 | 27,426.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 4,250.00 | 88.30 | 375,267.35 | 276,131.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2019-11-22 | Hamza Suria | President, CEO | Buy | 10,000.00 | 1.12 | 11,200.00 | 27,636.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 9,425.00 | 87.46 | 824,340.66 | 280,381.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-07-09 | Hamza Suria | President, CEO | Buy | 1,428.00 | 2.24 | 3,198.72 | 28,854.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 1,390.00 | 86.15 | 119,752.95 | 289,806.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 10,310.00 | 85.11 | 877,491.32 | 291,196.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2018-12-11 | Hamza Suria | President, CEO | Sell | 4,998.00 | 70.83 | 354,008.34 | 30,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-12 | Hamza Suria | President, CEO | Sell | 8,324.00 | 72.88 | 606,618.16 | 30,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-14 | Hamza Suria | President, CEO | Sell | 7,800.00 | 70.51 | 549,978.78 | 30,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm |
| 2019-01-14 | Hamza Suria | President, CEO | Sell | 12,240.00 | 71.10 | 870,304.39 | 30,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm |
| 2018-04-16 | Nicholas Lydon | Director | Sell | 2,600.00 | 84.18 | 218,879.96 | 301,506.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm |
| 2019-06-10 | Hamza Suria | President, CEO | Sell | 8,540.00 | 72.64 | 620,384.88 | 31,524.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm |
| 2019-06-04 | Marco Londei | Chief Medical Officer | Buy | 10,060.00 | 0.70 | 7,042.00 | 32,437.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 3,554.00 | 70.34 | 249,974.14 | 33,446.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2018-07-09 | Hamza Suria | President, CEO | Buy | 6,208.00 | 1.61 | 9,994.88 | 35,062.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm |
| 2018-12-10 | Hamza Suria | President, CEO | Sell | 4,964.00 | 72.48 | 359,805.12 | 35,062.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2019-12-10 | J. Anthony Ware | Director | Buy | 3,600.00 | 14.05 | 50,580.00 | 3,600.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Buy | 37,000.00 | 11.34 | 419,580.00 | 37,000.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |
| 2019-01-15 | Marco Londei | Chief Medical Officer | Sell | 4,181.00 | 69.29 | 289,686.44 | 37,271.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm |
| 2020-02-05 | Hamza Suria | President, CEO | Buy | 10,000.00 | 1.12 | 11,200.00 | 37,636.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm |
| 2018-12-14 | Hamza Suria | President, CEO | Sell | 9,084.00 | 69.68 | 632,967.67 | 37,864.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm |
| 2018-12-12 | Hamza Suria | President, CEO | Sell | 9,673.00 | 71.92 | 695,717.95 | 38,388.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-10 | Hamza Suria | President, CEO | Sell | 10,347.00 | 71.49 | 739,700.82 | 40,026.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2019-04-17 | Hamza Suria | President, CEO | Buy | 10,000.00 | 1.12 | 11,200.00 | 40,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm |
| 2019-01-15 | Marco Londei | Chief Medical Officer | Buy | 19,075.00 | 6.93 | 132,189.75 | 41,452.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm |
| 2019-01-14 | Hamza Suria | President, CEO | Sell | 27,760.00 | 70.65 | 1,961,227.34 | 42,304.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm |
| 2018-12-14 | Hamza Suria | President, CEO | Sell | 24,844.00 | 68.89 | 1,711,428.63 | 46,948.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm |
| 2020-03-10 | Hamza Suria | President, CEO | Buy | 10,000.00 | 1.12 | 11,200.00 | 47,636.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm |
| 2018-12-12 | Hamza Suria | President, CEO | Sell | 12,003.00 | 71.11 | 853,480.52 | 48,061.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-10 | Hamza Suria | President, CEO | Sell | 15,276.00 | 70.57 | 1,078,082.31 | 50,373.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-12 | Hamza Suria | President, CEO | Buy | 30,000.00 | 1.12 | 33,600.00 | 60,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2018-12-10 | Hamza Suria | President, CEO | Buy | 30,587.00 | 1.12 | 34,257.44 | 65,649.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm |
| 2019-11-27 | Marco Londei | Chief Medical Officer | Buy | 46,202.00 | 6.93 | 320,179.86 | 68,579.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm |
| 2019-01-14 | Hamza Suria | President, CEO | Buy | 40,000.00 | 1.12 | 44,800.00 | 70,064.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm |
| 2018-12-14 | Hamza Suria | President, CEO | Buy | 41,728.00 | 1.12 | 46,735.36 | 71,792.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm |
| 2018-12-03 | Dominic Piscitelli | Chief Financial Officer | Sell | 2,298.00 | 73.18 | 168,158.68 | 7,724.00 | https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm |